Pioneering Research and Transforming Patient Care
At Geistek Pharmaceuticals, we are at the forefront of oncology research, driving innovation and revolutionizing cancer treatment. With a deep understanding of the complex nature of cancer and the urgent need for effective therapies, we are committed to conducting early phase oncology trials that accelerate the development of breakthrough treatments.
Our expertise extends to immuno-oncology, where we recognize the transformative potential of immunotherapies in cancer treatment. By embracing novel approaches to clinical trials, we are paving the way for groundbreaking advancements in immuno-oncology, bringing hope to patients and redefining the standard of care.
We are also actively involved in the development of cell and gene therapies, recognizing the unique challenges they present to traditional clinical trial models. With an unwavering commitment to innovation, we are exploring new frontiers in cancer treatment, harnessing the power of living therapies to provide novel and life-changing solutions.
Geistek Pharmaceuticals conducts clinical studies across a wide range of solid and hematological tumors, including breast, lung, gastric, hepatocellular carcinoma (HCC), prostate, multiple myeloma, acute myeloid leukemia (AML), lymphoma, and leukemia. Through our comprehensive research efforts, we are striving to transform the landscape of oncology and improve outcomes for patients worldwide.
By partnering with leading experts, research institutions, and patient advocacy groups, we foster collaboration and knowledge exchange, enabling us to accelerate the development of innovative therapies. Together, we are dedicated to making a lasting impact on the lives of cancer patients and their families.
INTRODUCTION Tecartus is a new advanced therapy approved to treat adults with mantle cell lymphoma (MCL)¹. This disease is a lymphatic system cancer. Specifically, it
INTRODUCTION Kymriah (Novartis) is an advanced therapy medicine that belongs to the gene therapyproduct category. It is approved for B-cell acute lymphoblastic leukemia (ALL) in
INTRODUCTION ¹. CARVYKTI™ (ciltacabtagene autoleucel – Johnson & Johnson) was approved by the U.S. Food and Drug Administration (FDA) in February 2022 for the treatment
